Michael F. Roizen, MD, is a Phi Beta Kappa graduate of Williams College and Alpha Omega Alpha graduate of the University of California, San Francisco, School of Medicine. He performed his residency in internal medicine at Harvard's Beth Israel Hospital and completed Public Health Service at the National Institutes of Health in the laboratory of Irv Kopin and Nobel Prize winner Julius Axelrod. He is certified by both the American Boards of Internal Medicine and of Anesthesiology. Dr. Roizen is the Cofounder and Chair of the RealAge, Inc., Scientific Advisory Board. He is 62 calendar years of age, but his RealAge is 42.8.
Dr. Roizen is a Past Chair of a Food and Drug Administration advisory committee and a former editor for six medical journals. He has published more than 165 peer-reviewed scientific papers, 100 textbook chapters, 30 editorials, and four medical books (one, a medical best-seller), and received 13 U.S. and many foreign patents. He is one of the cofounders of the website RealAge.com, recently sold to the Hearst Corp., and still chairs its Scientific Advisory Board. One of the drugs he co-invented and developed (licensed to Progenics and Wyeth Corp.) for hospice patients will have its NDA day in 2008.
After nine years on the faculty at the University of California, San Francisco, he chaired the top-10-rated Department of Anesthesia and Critical Care at the University of Chicago. He then became Dean of the School of Medicine and Vice President for Biomedical Sciences at SUNY Upstate. After serving as CEO of the Biotechnology Research Corporation of Central New York, he accepted a position as Chair of the Anesthesiology Institute at Cleveland Clinic, responsible for over 180 operatories, 124 critical care beds and 28 pain therapy intervention units. In 2007, Dr. Roizen was named Chief Wellness Officer at Cleveland Clinic, the first such position in a major healthcare institution in the United States. Dr. Roizen also serves as Chairman of the Wellness Institute at Cleveland Clinic.